Evolent Health EVH 深 沪
等待开盘 10-24 09:30:00 美东时间
7.50
-0.580
-7.18%
华盛通- 最 高8.08
- 今 开8.06
- 成交量 357.22万股
- 最 低 7.44
- 昨 收 8.08
- 总市值 8.85亿
- 52周最高 25.22
- 市盈率 静 --
- 换手率 3.03%
- 52周最低 7.06
- 委 比 -56.90%
- 总股本 1.18亿
- 历史最高 39.779
- 量 比 2.25
- 振 幅 7.92%
- 历史最低 3.50
- 每 手 1
- 风险率 3.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Freshpet appoints Ivan Garcia as interim CFO
Freshpet (NASDAQ:FRPT) on Tuesday said announced that it has appointed Ivan Garcia as interim Chief Financial Officer, effective October 17, 2025. Garcia, currently serves as the Vice President of Fin...
10-08 04:36
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
Privia Health收购Evolent的ACO业务以强化价值医疗模式
Privia Health Group， Inc． PRVA 周二同意从Evolent Health， Inc． EVH 收购其负责任医疗组织业务。 ...
09-25 02:17
Stephens & Co. Reiterates Equal-Weight on Evolent Health, Maintains $9 Price Target
Stephens & Co. analyst Jeff Garro reiterates Evolent Health (NYSE:EVH) with a Equal-Weight and maintains $9 price target.
09-24 20:28
Evolent Health Affirms Q3 Sales Guidance of $460.000M-$480.000M vs $473.745M Est
Evolent Health (NYSE:EVH) affirms Q3 sales outlook from $460.000 million-$480.000 million to $460.000 million-$480.000 million vs $473.745 million estimate.
09-24 05:36
Evolent Health Affirms FY2025 Sales Guidance of $1.850B-$1.880B vs $1.884B Est
Evolent Health (NYSE:EVH) affirms FY2025 sales outlook from $1.850 billion-$1.880 billion to $1.850 billion-$1.880 billion vs $1.884 billion estimate.
09-24 05:36
Privia Health acquires Accountable Care Organization business from Evolent Health
Privia Health Group (PRVA) signed on Tuesday a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health (NYSE:EVH). Privia Health to pay $100M in cash at clo...
09-24 05:15
Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners
Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path. Proceeds from the transaction to be used to prepay senior term debt; Immediately acc...
09-24 04:10
Portillo’s appoints chairman as interim CEO amid leadership transition
Portillo’s (NASDAQ:PTLO) has named Michael A. Miles, Jr. as interim CEO, effective immediately. Miles succeeds Michael Osanloo, who has stepped down as president, CEO, and board member. Osanloo will r...
09-23 04:27
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
